GlassScriptPhysician profile
Richard D Murphy
NPI 1083077515
$1,302.47
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $188 · 2020: $295 · 2021: $424 · 2022: $76.73 · 2023: $282 · 2024: $37.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $319.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $169.09 | 2019-2024 | Breztri, Farxiga |
| Amgen INC. | $159.97 | 2020-2023 | Otezla, Repatha, Evenity |
| Novartis Pharmaceuticals Corporation | $124.41 | 2019-2023 | |
| Pfizer INC. | $115.49 | 2020-2023 | |
| Arbor Pharmaceuticals, INC. | $114.69 | 2021 | |
| Lilly USA, LLC | $111.82 | 2019-2023 | Mounjaro |
| Novo Nordisk INC | $98.78 | 2019-2020 | |
| Medtronic, INC. | $69.23 | 2021 | |
| Glaxosmithkline, LLC. | $68.56 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Currax Pharmaceuticals LLC | $63.43 | 2021-2022 | |
| Astellas Pharma US INC | $47.90 | 2019-2020 | |
| Abbvie INC. | $31.38 | 2021-2024 | |
| Allergan, INC. | $29.99 | 2020 | |
| Sumitomo Pharma America, INC. | $21.66 | 2023 | Gemtesa |
| Sunovion Pharmaceuticals INC. | $18.40 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $17.32 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.59 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $13.05 | 2021 | |
| Azurity Pharmaceuticals, INC. | $12.71 | 2023 | Adthyza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.